Lipofer (Iron Pyrophosphate)

Lipofer is a microencapsulated iron pyrophosphate ingredient developed by Indena, in which ferric iron is encapsulated in a phospholipid matrix to improve mucosal uptake via intestinal absorption pathways. This delivery system is designed to reduce the oxidative reactivity of free ionic iron, theoretically lowering gastrointestinal irritation while maintaining bioavailability comparable to or exceeding standard ferric pyrophosphate.

Origin & History

Lipofer is a branded, micronized and microencapsulated form of ferric pyrophosphate (Fe₄(P₂O₇)₃), a synthetic iron compound produced by reacting iron(III) chloride with sodium pyrophosphate or heating iron(III) metaphosphate under oxygen. The microencapsulation process coats ultra-fine ferric pyrophosphate particles with lipids like lecithin to enhance food compatibility and limit dietary inhibitor interactions.

Historical & Cultural Context

No historical or traditional medicinal use is documented for Lipofer or ferric pyrophosphate, as it is a modern synthetic compound developed specifically for iron fortification without roots in traditional medicine systems.

Health Benefits

• Iron deficiency treatment with reduced gastrointestinal side effects compared to free iron (manufacturer claims, no clinical trials provided)
• Enhanced iron absorption showing 3.5x higher bioavailability than standard ferric pyrophosphate (animal study referenced, study design not specified)
• No metallic taste or pro-oxidative activity detected (technical reports, human evidence not available)
• Better dispersibility in food matrices for fortification purposes (technical specifications only)
• Potentially improved iron storage through enhanced transferrin-to-ferritin transfer mechanisms (mechanistic data only, no clinical validation)

How It Works

Lipofer delivers ferric iron (Fe³⁺) encapsulated within a phospholipid bilayer, which facilitates uptake across intestinal epithelial cells by protecting the iron from luminal pH fluctuations and reducing pro-oxidant interactions with gut mucosa. Once absorbed, ferric iron is reduced to ferrous iron (Fe²⁺) by duodenal cytochrome b (Dcytb) reductase, enabling transport via divalent metal transporter 1 (DMT1) into enterocytes. Iron then enters systemic circulation bound to transferrin, where it is utilized for hemoglobin synthesis and cellular metabolic functions.

Scientific Research

The research dossier reveals no human clinical trials, RCTs, or meta-analyses specifically for Lipofer, with no PubMed PMIDs provided. Available evidence consists of manufacturer technical reports referencing one CSIC animal study showing 3.5x better bioavailability than ferric pyrophosphate and 2.7x better than ferrous sulfate, though study design and sample size were not specified.

Clinical Summary

Evidence for Lipofer's efficacy is currently limited; manufacturer-cited data reference an animal study suggesting approximately 3.5-fold higher bioavailability than standard ferric pyrophosphate, but the study design, species, and sample size have not been publicly disclosed in peer-reviewed literature. No published randomized controlled trials in human subjects have been identified as of the available data, meaning claims of reduced gastrointestinal side effects relative to ferrous sulfate or ferric salts remain manufacturer-level assertions rather than clinically validated findings. The broader class of microencapsulated iron compounds has shown promise in food fortification contexts, but Lipofer-specific human pharmacokinetic data are lacking. Consumers and clinicians should treat efficacy and tolerability claims with caution pending robust human trial data.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable"}, "micronutrients": {"iron": {"compound": "Iron Pyrophosphate", "approximate_concentration": "Varies by formulation, typically around 10-20 mg per serving", "bioavailability": "Enhanced absorption with 3.5x higher bioavailability than standard ferric pyrophosphate"}}, "bioactive_compounds": {"pro-oxidative_activity": "None detected"}, "vitamins": "Not applicable"}

Preparation & Dosage

No clinically studied dosage ranges for Lipofer are available from human trials. Technical reports indicate it contains approximately 8.12% elemental iron in liposomal variants, supplied as a fine, dispersible powder for food fortification. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, B12, Folate, Copper, Vitamin A

Safety & Interactions

Iron supplementation in general is contraindicated in individuals with hemochromatosis, hemosiderosis, or other iron overload disorders, and Lipofer carries the same contraindication profile as other iron-containing supplements. Common iron-related side effects including constipation, nausea, and dark stools may theoretically be reduced with the microencapsulated form, but this has not been confirmed in controlled human trials. Iron can inhibit the absorption of quinolone and tetracycline antibiotics, levothyroxine, and bisphosphonates when taken concurrently; a minimum two-hour separation is generally recommended. Pregnancy safety follows standard iron supplementation guidance — iron is essential during pregnancy, but dosing should be supervised by a healthcare provider to avoid excess, and pediatric dosing requires careful weight-based calculation to prevent toxicity.